Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) EPS (Basic) (2017 - 2021)

Cogent Biosciences has reported EPS (Basic) over the past 5 years, most recently at -$0.62 for Q4 2021.

  • Quarterly results put EPS (Basic) at -$0.62 for Q4 2021, up 92.8% from a year ago — trailing twelve months through Dec 2021 was -$1.87 (up 87.89% YoY), and the annual figure for FY2025 was -$2.16, down 11.34%.
  • EPS (Basic) for Q4 2021 was -$0.62 at Cogent Biosciences, down from -$0.48 in the prior quarter.
  • Over the last five years, EPS (Basic) for COGT hit a ceiling of $0.07 in Q4 2019 and a floor of -$8.61 in Q4 2020.
  • Median EPS (Basic) over the past 5 years was -$0.58 (2017), compared with a mean of -$1.18.
  • Biggest five-year swings in EPS (Basic): soared 124.14% in 2019 and later crashed 12400.0% in 2020.
  • Cogent Biosciences' EPS (Basic) stood at -$0.66 in 2017, then surged by 56.06% to -$0.29 in 2018, then soared by 124.14% to $0.07 in 2019, then crashed by 12400.0% to -$8.61 in 2020, then skyrocketed by 92.8% to -$0.62 in 2021.
  • The last three reported values for EPS (Basic) were -$0.62 (Q4 2021), -$0.48 (Q3 2021), and -$0.43 (Q2 2021) per Business Quant data.